Although several novel biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin18 (IL-18), have been introduced to identify early AKI before creatinine rise, the utility is confined to research and clinical applicability is impeded (4–6). This evidence concerns the gene IL18 and acute kidney injury.